Investor Alert

press release

Sept. 27, 2021, 6:30 a.m. EDT

Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sep 27, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Chardan Virtual 5 [th] Annual Genetics Medicines Conference on Monday, October 4, 2021 at 11:00 a.m. ET. Dr. Kathiresan will also participate in a panel titled, "Genetic Medicines: The Ongoing Emergence of the Heart as a Target Tissue Panel" on Monday, October 4, 2021 at 3:00 p.m. ET.

A live webcast of the fireside chat will be available in the investor section of the company's website at www.vervetx.com . The webcast will be archived for 60 days following the presentation.

About Verve Therapeutics
Verve Therapeutics, Inc. /zigman2/quotes/227446048/composite VERV -3.24% is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com .

Media Contact
Gina Nugent, 617-460-3579
Ten Bridge Communications

Investor Contact
Monique Allaire
THRUST Strategic Communications


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

US : U.S.: Nasdaq
$ 30.80
-1.03 -3.24%
Volume: 915,039
Jan. 25, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.53 billion
Rev. per Employee

Partner Center

Link to MarketWatch's Slice.